Xylocaine
® revolutionized local and regional anaesthesia in the early 1950s, but the patent was due to expire in 1965 and Astra was anxious to produce a successor. The research was led by Nils Löfgren again and he worked steadily back through all the compounds they had investigated in the development of xylocaine. He concluded that a drug with fewer side-effects than xylocaine would be marketable as a successor and this became the focus of the research. It is interesting to note the change in focus; originally the researchers had been driven to find a perfect local anaesthetic, now they were searching for a marketable drug.
The search uncovered L67, a compound which had been synthesized by Löfgren and Claes Tegnér in 1953. It had almost the same properties as xylocaine but appeared to have about half the toxicity. However, before Astra could begin clinical trials with L67, Ekenstam, a chemist at a rival Swedish company, Bofors, produced two new compounds-mepivacaine and bupivacaine. Both were significant developments but bupivacaine more so because of its long duration of action.
Astra continued the development of L67 but began legal proceedings against Bofors for breach of patent. Clinical trials were begun and it was released on to the market as prilocaine (Citanest ® ) in 1963. Citanest was not a great success, probably because it was an unnecessary development. Once the xylocaine patent expired, Astra discovered that their worries had been groundless. Xylocaine was so well established and regarded that the brand meant more than the patent and sales continued to rise.
There was also a problem with the metabolism of prilocaine. O-toludine is produced as a breakdown product and can lead to methaemoglobinaemia. This is a dose-related problem and is only a significant issue in small children but it was to prove a psychological barrier to its use. Prilocaine found a place in intravenous arm blocks due to its low toxicity but has never been widely accepted in any other area. Towards the end of the 1970s chemists at Astra discovered that a mixture of xylocaine and prilocaine produced a highly concentrated liquid which could be used in emulsions. This product was introduced as EMLA ® cream which is now widely used for topical application prior to venipuncture and is evidence of the remarkable ongoing success of xylocaine.
Mepivacaine was synthesized in 1956 and released the following year as Carbocaine ® in direct competition to xylocaine. It is a comparable drug with a similar onset time but slightly longer duration of action. William Sheffield and colleagues studied 1246 regional anaesthetics for various procedures. They concluded that mepivacaine was "valuable for the production of safe and satisfactory regional anaesthesia for operative purposes". However, mepivacaine is not effective topically and there were problems in obstetrics due to the limited ability of the fetus to metabolize mepivacaine. For these reasons, and because xylocaine was so well established, mepivacaine never really found widespread acceptance.
The following year Bofors developed bupivacaine, a homologue of mepivacaine, which was a more significant competitor to xylocaine. It was released into clinical practice as Marcain ® in 1963 and was initially available in solutions ranging from 0.25% to 0.75%. All solutions were compatible with adrenaline and a hyperbaric spinal solution was subsequently introduced. Bupivacaine's greatest advantage was its longer duration of action.
Lund and colleagues in Pennsylvania conducted early clinical and laboratory studies in the U.S.A. and concluded that the long duration of action often obviated the need for peridural anaesthesia. They also found that bupivacaine had obvious benefits in the management of postoperative pain as the anaesthesia often lasted well into the postoperative period. This had disadvantages as well, as some patients became very anxious when brachial plexus blocks persisted hours after the surgery. The prolongation of the sympathetic block with epidurals was also problematic in some of their patients who required closer observations and medical intervention in the recovery room.
Bupivacaine produced a more selective sensory blockade with less motor block. This meant that it was not as useful as had been hoped for upper abdominal surgery under spinal anaesthesia. It did have great advantages in obstetrics and quickly became the drug of choice for epidurals in labour. Initially the 0.75% was extremely popular for this purpose.
As well as a longer duration of action, bupivacaine was four times more potent than xylocaine and consequently more toxic. It was discovered to have significant cardiac toxicity and eventually the 0.75% solution was withdrawn. Prior to this, several deaths had been reported when bupivacaine was used for intravenous arm blocks. In others, inadvertent intravenous administration had resulted in cardiovascular collapse which proved peculiarly resistant to resuscitation.
Astra's legal action against Bofors was unsuccessful, but in 1973 they acquired the rights to bupivacaine and mepivacaine and eventually acquired the company. Bupivacaine remained the drug of choice for all situations where long-acting anaesthesia and analgesia was required until very recently. Ropivacaine, a homologue of bupivacaine, also developed by Bofors and acquired by Astra, is now commercially available and has lower cardiac toxicity. Clearly there will be further developments but, since the synthesis of xylocaine, Astra has monopolized the local anaesthetic market and seems likely to maintain that position in the near future.
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